Oxford Biomedica Solutions
Jin Yin has extensive work experience in biomedica and pharmaceutical companies. They most recently worked at Oxford Biomedica Solutions as VP of Process Development. Prior to that, they worked at Homology Medicines, Inc. as Senior Director of Manufacturing Development & Technology. Before that, they held various roles at Momenta Pharmaceuticals, including Senior Director of Bioprocessing and Director of Biologics Process Development. Earlier in their career, they worked at Sanofi Genzyme as Associate Director of Commercial Cell Culture Development, at Shire as Principal Engineer of Cell Culture Process Development, and at ID Biomedical / GSK Biologicals as a Scientist. Jin Yin began their career as a Postdoctoral Associate at the Massachusetts Institute of Technology.
Jin Yin has completed a B.S. in Chemical Engineering from Tsinghua University. Additionally, they have also obtained a Ph.D. in Chemical Engineering from the same institution. The specific years of enrollment or graduation are not provided.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.